Physicians' Academy for Cardiovascular Education

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Remarkable reduction of LCL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

Higher rate of smoking cessation with e-cigarettes compared to counseling

3' education - Apr. 1, 2020 - Prof. Mark Eisenberg, MD - ACC 2020

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

CAPACITY COVID: a registry of CV variables in patients with COVID-19

3' education - Mar. 31, 2020 - Prof. Folkert Asselbergs, MD, PhD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events

3' education - Mar. 29, 2020 - Dr. Marc P. Bonaca, MD - ACC 2020

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence

10' education - Mar. 29, 2020 - Prof. Menno Huisman - ACC 2020

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

Addressing CV risk: the role of statins and ezetimibe

5' education - Feb. 9, 2020 - Prof. Christopher Cannon, MD

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Renal denervation reduces BP in hypertensive patients in absence of medications

News - Apr. 2, 2020

ACC 2020 The SPYRAL HTN-OFF MED Pivotal Trial showed that renal denervation lowers 24h SBP and office SBP compared to sham control in hypertensive patients in absence of medications.

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020
The REDUCE-IT EPA study suggests that EPA levels are the predominant driver of CV benefit observed in the REDUCE-IT trial and high EPA levels are associated with a reduced risk of a variety of CV events.

ACC 2020 The REDUCE-IT EPA study suggests that EPA levels are the predominant driver of CV benefit observed in the REDUCE-IT trial and showed that high EPA levels are associated with a reduced risk of a variety of CV events.

Higher on-treatment EPA levels associated with reduced risk of CV outcomes

News - Apr. 2, 2020

ACC 2020 A sub-analysis of the REDUCE-IT trial, evaluating the effect of icosapent ethyl, showed that higher on-treatment levels of EPA were associated with a reduced risk in CV events.

Remarkable reduction of LCL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020
An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.

ACC 2020 An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.

PCSK9 inhibitor reduces LDL-c in patients with HoFH

News - Apr. 1, 2020

ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.

Higher rate of smoking cessation with e-cigarettes compared to counseling

3' education - Apr. 1, 2020 - Prof. Mark Eisenberg, MD - ACC 2020
Prof. Eisenberg explains the design of the trial with 3 randomisation arms and shares the findings of this short-term trial of 12 weeks.

ACC 2020 Prof. Eisenberg explains the design of the trial with 3 randomisation arms and shares the efficacy and safety findings of e-cigarettes in this short-term trial of 12 weeks.

The CAPACITY COVID registry: a call to collect CV data of COVID-19 patients

News - Mar. 31, 2020
An initiative of cardiologists and the Dutch CardioVascular Alliance has resulted in the start of the CAPACITY COVID registry, to collect CV data of COVID-19 patients. The initiators call to join now!

An initiative of cardiologists and the Dutch CardioVascular Alliance has resulted in the start of the CAPACITY COVID registry, to collect CV data of COVID-19 patients. The initiators call to join now!

Phase III trial with SGLT2i in CKD patients stopped early due to overwhelming efficacy

News - Mar. 31, 2020

The phase III DAPA-CKD trial evaluating the effectivity of SGLT2 inhibitor dapagliflozin in patients with CKD will be stopped early due to overwhelming benefit.

Angiopoietin-like protein 3 inhibitor reduces LDL-c in homozygous FH

News - Mar. 31, 2020

ACC 2020 This study showed that the angiopoietin-like protein 3 inhibitor evinacumab substantially reduces LDL-c in patients with homozygous Familial Hypercholesterolemia (HoFH), regardless of LDL receptor function.

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020
The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

CAPACITY COVID: a registry of CV variables in patients with COVID-19

3' education - Mar. 31, 2020 - Prof. Folkert Asselbergs, MD, PhD
Prof. Asselbergs calls to participate in the CAPACITY COVID-19 registry, a CV supplement to the existing ISARIC and WHO registry, to collect information on CV variables.

Prof. Asselbergs calls to participate in the CAPACITY COVID-19 registry, a CV supplement to the existing ISARIC and WHO registry, to collect information on CV variables during the COVID-19 pandemic.

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020
Anticoagulant monotherapy reduced bleeding compared to anticoagulant therapy plus clopidogrel, without increasing ischemic events in AF patients undergoing TAVI.

ACC 2020 Oral anticoagulant monotherapy reduced bleeding compared to anticoagulant therapy plus clopidogrel, without increasing ischemic events in AF patients undergoing TAVI.